The US FDA had inspected Aurobindo’s Unit-7 between January 28 and February 10, 2026. The inspection observations pointed to multiple lapses in manufacturing and quality control processes.
The US FDA had inspected Aurobindo’s Unit-7 between January 28 and February 10, 2026. The inspection observations pointed to multiple lapses in manufacturing and quality control processes.